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Creatine Kinase-MB Elevation
Following Stent Implantation
We read with interest the study by Jeremias et al. (1) published in
the Journal. The investigators claim that creatine kinase-MB
fraction (CK-MB) elevations following stent deployment portend
an unfavorable prognosis only for patients with unsuccessful
procedures. Although this finding may be true, we have several
reservations.
The researchers do not provide the absolute number of deaths;
however, it can be indirectly inferred from the presented total
number of patients and event rates that their entire study includes
only 10 deaths among patients with an unsuccessful procedure and
about 100 more deaths in patients with successful procedures. The
main inferences are practically based on 10 deaths. Such small
numbers do not allow any meaningful modeling in CK-MB strata
or multivariate analyses.
Furthermore, the use of percentages is misleading here; for
example, the 5% death rate on patients with type 2 myocardial
infarction (MI) and unsuccessful procedure is based on a single
death, and the 9.1% death rate on patients with type 1 MI is based
on only two deaths! Even the unadjusted analyses are based on
extremely thin information. The successful procedure data are also
limited: the observed differences of 0.4% to 0.7% excess death rate
with small CK-MB elevations are certainly not statistically signif-
icant given the small number of events, but they may be clinically
important when extrapolated to the millions of patients who
undergo “successful” procedures.
Moreover, the overall one-year death rate in the study by
Jeremias et al. is only 2%, whereas it has been about 4% in other
studies evaluating peri-procedural MI (2). The same relative risk
increase would have a larger absolute magnitude in a population at
higher baseline risk of death.
We are also concerned that the details of the study protocols
and justification of data pooling as described in the study by
Jeremias et al. (1) are not fully described in the cited reference (see
reference 8 in their report). The definition of “unsuccessful”
procedure is not standardized in the published data. The definition
of Jeremias et al. comprises five different elements (stenosis, flow
grade, dissection, repeat revascularization, stent thrombosis). Each
of these may be selected with different cutoffs (e.g., stenosis 50%
or 30%; dissection D or C; Thrombolysis In Myocardial
Infarction [TIMI] flow grade 3 or other criteria). Some inves-
tigators may use only some (3,4), but not all, of these criteria, or
may add other parameters (5). In a database of 6,186 patients, it is
almost certain that definition changes can always allow identifica-
tion of a minuscule group of about 100 patients where 10 deaths
have occurred and thus support a claim that this is the high-risk
group par excellence.
Overall, such claims about high-risk groups are primarily
hypothesis-generating speculations. It is important to try to
replicate these findings in other patient cohorts using the exact
same definitions. Chances are that the greater the degree of
selection and strict data-fitting in the original investigation, the
less likely the findings are replicated elsewhere (6). Nevertheless,
given the great clinical importance of the observations made by
Jeremias et al. (1), such validation is essential.
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REPLY
We thank Dr. Ioannidis and colleagues for their interest in our
study (1), in which we hypothesized that procedure success would
have a significant effect on the reported association between
mortality and peri-procedural creatine kinase-MB fraction (CK-
MB) elevation. Dr. Ioannidis and colleagues have raised concerns
regarding insufficient numbers of patients and events to adequately
address the question, justification for pooling of the clinical trial
data, interpretation of the small absolute risk difference, and a
definition of procedure success that is not standardized in the
published data.
These same investigators have published a meta-analysis of
23,230 patients (including ACS [acute coronary syndrome] and
vein graft interventions) treated by a mixture of stent, directional
coronary atherectomy, and balloon angioplasty over a decade,
showing a one-year mortality risk of 3.5% with normal CK-MB,
rising to 5.2%, 6.3%, and 10.9% for CK-MB 1 to 3, 3 to 5, and5
times normal, respectively (2). What such meta-analyses gain in
numbers of patients and events may be lost in lack of detail about
those patients—for instance, whether the effect holds true for
stenting (as used in 90% of current interventions), and whether it
applies equally to incidental CK-MB elevations seen after other-
wise successful procedures. Our study is actually one of the largest
reports after elective stenting, with nearly 6,000 patients and over
100 death events, and includes data pooled at the patient-by-patient
level, so that it could look into the question with greater granu-
larity. The pooling of the trials was fully justified based on the
nearly identical inclusion criteria and baseline clinical and angio-
graphic characteristics (3,4). The one-year mortality was similar to
other elective stent populations (5) and was essentially flat for
normal-to-moderate level CK-MB elevations among successful
procedures, whereas mortality was over six times higher in patients
with unsuccessful procedures and any elevation in CK-MB.
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